About Boston Scientific Corporation Common Stock
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries.
2BB score and signals
Boston Scientific Corporation Common Stock’s current 2BB score is 48 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 34 | Low |
| Momentum | 60 | Improving |
| Financial strength | 79 | Strong |
| Quality | 100 | Very Strong |
| Risk | 35 | Low |
Company facts
| CEO | Michael F. Mahoney |
| Headquarters | Marlborough, Massachusetts, United States |
| Founded | Jun 29, 1979 |
| Employees | 59K |
| P/E ratio | 18.93 |
| 52-week range | $42.20 – $109.50 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-02 | — | 0.846 | — | $5.48B |
| 2026-10-28 | — | 0.8133 | — | $5.30B |
| 2026-07-29 | — | 0.8352 | — | $5.42B |
| 2026-04-22 | 0.8 | 0.7945 | $5.20B | $5.22B |
Related companies
